10690458

```
=> d his

     (FILE 'HOME' ENTERED AT 18:46:44 ON 02 JUN 2004)

     FILE 'REGISTRY' ENTERED AT 18:46:57 ON 02 JUN 2004
                E AMONAFIDE/CN
L1              1 S E3
L2              1 S L1
                E MITONAFIDE/CN
L3              1 S E3

     FILE 'CAPLUS' ENTERED AT 18:48:27 ON 02 JUN 2004
L4             89 S L1
L5             55 S L3
L6            123 S L4 OR L5
L7              2 S L6 AND (MALEATE OR CITRATE OR FUMARATE OR GLYCOLATE OR MALONA
L8              1 S L6 AND MALATE

=>
```

10690458

```
=> s l1
L4           89 L1

=> s l3
L5           55 L3

=> s l4 or l5
L6          123 L4 OR L5

=> s l6 and (maleate or citrate or fumarate or glycolate or malonate or pyruvate or succinate or adipate
or aspartate or salicylate)
          28485 MALEATE
          76967 CITRATE
          16563 FUMARATE
           7643 GLYCOLATE
          22478 MALONATE
          48028 PYRUVATE
          46190 SUCCINATE
          19828 ADIPATE
          53909 ASPARTATE
          27878 SALICYLATE
L7            2 L6 AND (MALEATE OR CITRATE OR FUMARATE OR GLYCOLATE OR MALONATE
                OR PYRUVATE OR SUCCINATE OR ADIPATE OR ASPARTATE OR SALICYLATE)
```

10690458

=> d bib abs kwic

L7 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:521462 CAPLUS
DN 137:88442
TI Incensole and furanogermacrens and compounds in treatment for inhibiting neoplastic lesions and microorganisms
IN Shanahan-Pendergast, Elisabeth
PA Ire.
SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002053138	A2	20020711	WO 2002-IE1	20020102
	WO 2002053138	A3	20020919		
	W: AE, AG, AT, AU, BB, BG, CA, CH, CN, CO, CU, CZ, LU, LV, MA, MD, UA, UG, US, VN, YU, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, AT, BE, CH, CY, DE, ES, FI, ML, MR, NE, SN, TD, TG				
	EP 1351678	A2	20031015	EP 2002-727007	20020102
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2004092583	A1	20040513	US 2004-250535	20040102
PRAI	IE 2001-2	A	20010102		
	WO 2002-IE1	W	20020102		

OS MARPAT 137:88442
AB The invention discloses the use of incensole and/or furanogermacrens, derivs. metabolites and precursors thereof in the treatment of neoplasia, particularly resistant neoplasia and immundysregulatory disorders. These compds. can be administered alone or in combination with conventional chemotherapeutic, antiviral, antiparasite agents, radiation and/or surgery. Incensole and furanogermacren and their mixture showed antitumor activity against various human carcinomas and melanomas and antimicrobial activity against Staphylococcus aureus and Enterococcus faecalis.
IT 50-07-7, Mutamycin 50-18-0, Cyclophosphamide 50-28-2, Estradiol, biological studies 50-35-1, Thalidomide 50-76-0, Dactinomycin 50-91-9, Floxuridine 51-21-8, Fluorouracil 51-75-2, Mechlorethamine 52-24-4, Thiotepa 53-19-0, Mitotane 53-43-0, DHEA 53-79-2, Puromycin 54-71-7, Pilocarpine hydrochloride 54-91-1, Pipobroman 55-21-0D, Benzamide, N-substituted compds. 55-86-7, Mechlorethamine Hydrochloride 55-86-7D, Nitrogen mustard, derivs. 55-98-1, Busulfan 56-53-1, Diethylstilbestrol 57-22-7, Vincristine 57-63-6, Ethinyl oestradiol 57-83-0, Progesterone, biological studies 58-05-9, Leucovorin 58-58-2, Puromycin Hydrochloride 59-05-2, Methotrexate 66-75-1, Uracil Mustard 83-89-6, Acriquine 101-60-0, Porphyrin 106-60-5, Aminolevulinic acid 114-70-5, Sodium phenylacetate 122-79-2, Phenylacetate 125-45-1, Azetepa 125-84-8, Aminoglutethimide 127-07-1, Hydroxyurea 143-67-9, Vinblastine Sulfate 145-63-1, Suramin 147-94-4, Cytarabine 148-82-3, Melphalan 154-42-7, Thioguanine 154-93-8, Carmustine 302-49-8, Uredepa 302-79-4, Tretinoin 305-03-3, Chlorambucil 320-67-2, Azacitidine 359-83-1, Pentazocine 364-62-5, Metoclopramide 366-70-1, Procarbazine Hydrochloride 378-44-9, Betamethasone 423-55-2, Perflubron 459-86-9, Mitoguazone 465-65-6, Naloxone 472-15-1, Betulinic acid 481-29-8, Epiandrosterone 518-28-5, Podophyllotoxin 520-85-4, Medroxyprogesterone 521-12-0, Dromostanolone Propionate 536-59-4, Perillyl alcohol 548-04-9, Hypericin 566-48-3, Formestane 569-57-3, Chlorotrianisene 578-95-0D, Acridone, imidazo derivs. 578-95-0D, Acridone, propylbis derivs. 595-33-5, Megestrol Acetate 645-05-6, Altretamine 646-08-2, β-Alethine 671-16-9, Procarbazine 801-52-5, Porfiromycin 865-21-4, Vinblastine 911-45-5, Clomifene 968-93-4, Testolactone 1271-19-8, Titanocene dichloride 1402-81-9, Ambomycin 1403-99-2, Mitogillin 1404-00-8, Mitomycin 1404-15-5, Nogalamycin 1404-20-2, Peliomycin 1404-64-4, Sparsomycin 1661-29-6, Meturedepa 1972-08-3, Dronabinol 1980-45-6, Benzodepa 2068-78-2, Vincristine Sulfate 2353-33-5, Decitabine 2508-89-6 2608-24-4, Piposulfan 2809-21-4D, Etidronic acid, rhenium-186 complexes 2919-66-6, Melengestrol acetate 2998-57-4, Estramustine 2998-57-4D, Estramustine, analogs 3073-59-4, Hexamethylene bisacetamide 3094-09-5, Doxifluridine 3562-63-8, Megestrol 3778-73-2, Ifosfamide 3930-19-6, Streptonigrin 4105-38-8 4291-63-8, Cladribine 4342-03-4, Dacarbazine 4342-07-8 4803-27-4, Anthramycin 5072-26-4, Buthionine sulfoximine 5373-42-2, Thaliblastine 5508-58-7, Andrographolide 5579-27-1, Simtrazene 5581-52-2, Thiamiprine 5696-17-3, Epipropidine 6157-87-5, Trestolone Acetate 7281-31-4, Vinglycinate Sulfate 7440-06-4D, Platinum, lipophilic compds. or complexes 7440-06-4D, Platinum, triamine

complexes 7644-67-9, Azotomycin 7689-03-4D, Camptothecin, derivs. 7724-76-7, Riboprine 7761-45-7, Metoprine 8052-16-2, Cactinomycin 9002-71-5, Thyroid-stimulating hormone 9014-02-2, Zinostatin 9014-42-0, Thrombopoietin 9014-42-0D, Thrombopoietin, mimetics 9015-68-3, Asparaginase 9027-98-9 9041-93-4, Bleomycin Sulfate 9050-67-3, Sizofiran 10043-49-9, Gold-198, biological studies 10087-89-5, Enpromate 10318-26-0, Mitolactol 10403-51-7, Mitindomide 10540-29-1, Tamoxifen 11002-22-5, Apurinic acid 11029-06-4, Elemene 11043-98-4, Mitocromin 11043-99-5, Mitomalcin 11056-06-7, Bleomycin 11056-12-5, Cirolemycin 11056-14-7, Mitocarcin 11056-15-8, Mitosper 12713-07-4D, Verdin, compds. 13010-47-4, Lomustine 13311-84-7, Flutamide 13494-90-1, Gallium nitrate 13665-88-8, Mopidamol 13909-09-6, Semustine 14769-73-4, Levamisole 15475-56-6, Methotrexate Sodium 15639-50-6, Safingol 15663-27-1, Cisplatin 17021-26-0, Calusterone 17902-23-7, Tegafur 18378-89-7, Plicamycin 18416-85-8, Lombricine 18556-44-0, Vinrosidine Sulfate 18588-57-3, Etoprine 18883-66-4, Streptozocin 19916-73-5, O6-Benzylguanine 20098-14-0, Idramantone 20537-88-6, Amifostine 20638-84-0, Retinamide 20830-81-3, Daunorubicin 21059-48-3, Veramine 21679-14-1, Fludarabine 22668-01-5, Etanidazole 23214-92-8, Doxorubicin 23541-50-6, Daunorubicin Hydrochloride 23593-75-1, Clotrimazole 24280-93-1, Mycophenolic Acid 24584-09-6, Dexrazoxane 25316-40-9, Adriamycin 27302-90-5, Oxisuran 27314-97-2, Tirapazamine 27548-93-2D, Baccatin III, derivs. 27686-84-6, Masoprocol 29069-24-7, Prednimustine 29767-20-2, Teniposide 30303-65-2, Docosanol 30387-51-0, Asperlin 30868-30-5, Pyrazofurin 31430-18-9, Nocodazole 31441-78-8, Mercaptopurine 32954-58-8, Ipomeanol 33069-62-4, Paclitaxel 33069-62-4D, Paclitaxel, analogs and derivs. 33419-42-0, Etoposide 35301-24-7, Cedefingol 35846-53-8, Maytansine 35943-35-2, Triciribine 36508-71-1, Zorubicin Hydrochloride 37717-21-8, Flurocitabine 38270-90-5, Strontium Chloride Sr 89 38321-02-7, Dexverapamil 39325-01-4, Picibanil 40391-99-9, Pamidronic acid 41575-94-4, Carboplatin 41729-52-6, Dezaguanine 41992-22-7, Spirogermanium Hydrochloride 42228-92-2, Acivicin 42616-25-1, Methioninase 50264-69-2, Lonidamine 51264-14-3, Amsacrine 51321-79-0, Sparfosic acid 52128-35-5, Trimetrexate 52205-73-9, Estramustine Phosphate Sodium 52794-97-5, Carubicin Hydrochloride 53643-48-4, Vindesine 53714-56-0, Leuprolide 53910-25-1, Pentostatin 54081-68-4, Vinleurosine Sulfate **54824-17-8**, Mitonafide 55435-65-9, Acodazole Hydrochloride 56390-09-1, Epirubicin Hydrochloride 56420-45-2, Epirubicin 56605-16-4, Spiromustine 56741-95-8, Bropirimine 57381-26-7, Irsogladine 57576-44-0, Aclarubicin 57773-63-4, Triptorelin 57773-65-6, Deslorelin 57852-57-0, Idamycin 57998-68-2, Diaziquone 58066-85-6, Miltefosine 58525-82-9, Azatyrosine 58957-92-9, Idarubicin 58970-76-6, Ubenimex 59653-73-5, Teroxirone 59917-39-4, Vindesine Sulfate 59989-18-3, 5-Ethynyluracil 60084-10-8, Tiazofurin 60203-57-8, Prostaglandin J2 60940-34-3, Ebselen 61825-94-3, Oxaliplatin 61966-08-3, Triciribine Phosphate 62304-98-7, Thymalfasin 62435-42-1, Perfosfamide 62488-57-7 62816-98-2, Ormaplatin 62928-11-4, Iproplatin 63590-19-2, Balanol 63612-50-0, Nilutamide 63950-06-1, Esorubicin Hydrochloride 65057-90-1, Talisomycin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT 65093-40-5, Cytarabine ocfosfate 65222-35-7, Pazelliptine 65271-80-9, Mitoxantrone 65646-68-6, Fenretinide 65807-02-5, Goserelin 65886-71-7, Fazarabine 66569-27-5, Sparfosate Sodium 66849-34-1, Dexifosfamide 67699-41-6, Vinzolidine Sulfate 68278-23-9, Eflornithine Hydrochloride 68475-42-3, Anagrelide 69839-83-4, Didox 70052-12-9, Eflornithine 70384-29-1, Peplomycin Sulfate 70476-82-3, Mitoxantrone Hydrochloride 70641-51-9, Edelfosine 70711-40-9, Ametantrone Acetate 71294-60-5, Rohitukine 71439-68-4, Bisantrene Hydrochloride 71486-22-1, Vinorelbine 71522-58-2, Forfenimex 71628-96-1, Menogaril 72238-02-9D, Retelliptine, demethyl derivs. 72496-41-4, Pirarubicin 72629-69-7, Sarcophytol A 72732-56-0, Piritrexim 72741-87-8, Swainsonine 73105-03-0, Pentamustine 74149-70-5, Parabactin 74381-53-6, Leuprolide Acetate 74790-08-2, Spiroplatin 75219-46-4, Atrimustine 75330-75-5, Lovastatin 75607-67-9, Fludarabine Phosphate 75775-33-6D, Purpurin, compds. 75957-60-7, Splenopentin 76932-56-4, Nafarelin 77016-85-4, Plomestane 77327-05-0, Didemnin B 77599-17-8, Panomifene 77858-21-0, Velaresol 78113-36-7, Romurtide 78186-34-2, Bisantrene 79778-41-9, Neridronic acid 79831-76-8, Castanospermine 80451-05-4, Cecropin B 80576-83-6, Edatrexate 80663-95-2 80841-47-0, Asulacrine 81424-67-1, Caracemide 81965-43-7, SarCNU 82230-03-3, Carbetimer 82413-20-5, Droloxifene 82707-54-8, Neutral endopeptidase 82855-09-2D, Combretastatin, analogs 82952-64-5, Trimetrexate

Glucuronate 83086-73-1, Tubulozole Hydrochloride 83150-76-9, Octreotide 83200-11-7, Vinepidine Sulfate 83519-04-4, Ilmofosine 83997-75-5, Iododoxorubicin 84030-84-2, Telluropyrylium 84088-42-6, Roquinimex 84371-65-3, Mifepristone 84412-94-2, Ruboxyl 85465-82-3, Thymotrinan 85622-93-1, Temozolomide 85754-59-2, Ambamustine 85969-07-9, Budotitane 85977-49-7, Tauromustine 86976-56-9, Betaclamycins 87005-03-6, Panaxytriol 87434-82-0, Dezaguanine Mesylate 87806-31-3, Porfimer Sodium 87810-56-8, Fostriecin 87860-39-7, Fostriecin Sodium 88303-60-0, Losoxantrone 88303-61-1, Losoxantrone Hydrochloride 89565-68-4, Tropisetron 89778-26-7, Toremifene 89778-27-8, Toremifene **Citrate** 90357-06-5, Bicalutamide 90996-54-6, Rhizoxin 92047-76-2, Tetrachlorodecaoxide 92118-27-9, Fotemustine 92788-10-8, Rogletimide 92803-82-2, Aphidicolin glycinate 94079-80-8, Cicaprost 95058-81-4, Gemcitabine 95734-82-0, Nedaplatin 95933-72-5, Amidox 96201-88-6, Brequinar Sodium 96301-34-7, Atamestane 96346-61-1, Onapristone 96389-68-3, Crisnatol 96389-69-4, Crisnatol Mesylate 96392-96-0, Dexormaplatin 96892-57-8, Hepsulfam 97068-30-9, Elsamitrucin 97534-21-9, Merbarone 97682-44-5, Irinotecan 97752-20-0, Droloxifene **Citrate** 97919-22-7 98319-26-7, Finasteride 98383-18-7, Ecomustine 98631-95-9, Sobuzoxane 99009-20-8, Pyrazoloacridine 99011-02-6, Imiquimod 99283-10-0, Molgramostim 99614-02-5, Ondansetron 100286-90-6, Irinotecan Hydrochloride 100324-81-0, Lisofylline 102396-24-7, Jasplakinolide 102676-31-3, Fadrozole Hydrochloride 102676-47-1, Fadrozole 102822-56-0, Mannostatin A 103222-11-3, Vapreotide 103612-80-2 104493-13-2, Adecypenol 105118-12-5, Piroxantrone Hydrochloride 105149-04-0, Osaterone 105615-58-5, Oxaunomycin 105844-41-5, Plasminogen activator inhibitor 106096-93-9D, Basic Fibroblast growth factor, saporin conjugates 106400-81-1, Lometrexol 107000-34-0, Zanoterone 107256-99-5, Tamoxifen methiodide 107868-30-4, Exemestane 108736-35-2, Lanreotide 108852-90-0, Nemorubicin 109837-67-4, Cycloplatam 110267-81-7, Amrubicin 110311-27-8, Sulofenur 110314-48-2, Adozelesin 110690-43-2, Emitefur 110942-02-4, Aldesleukin 110942-08-0, Luprolide 111490-36-9, Zeniplatin 111523-41-2, Enloplatin 112515-43-2, Topsentin 112522-64-2, Acetyldinaline 112809-51-5, Letrozole 112859-71-9, Fluasterone 112887-68-0, Raltitrexed 112965-21-6, Calcipotriol 114084-78-5, Ibandronic acid 114285-68-6, Lentinan sulfate 114517-02-1, Fosquidone 114977-28-5, Taxotere 115150-59-9, Antagonist G 115308-98-0, Tallimustine 115566-02-4, Bistratene A 115575-11-6, Liarozole 115956-12-2, Dolasetron 116057-75-1, Idoxifene 117048-59-6, Combretastatin A4 117091-64-2, Etoposide Phosphate 118292-40-3, Tazarotene 119169-78-7, Epristeride 119413-54-6, Topotecan Hydrochloride 119813-10-4, Carzelesin 120287-85-6, Cetrorelix 120408-07-3, Lometrexol Sodium 120500-15-4, Leinamycin 120511-73-1, Anastrozole 120685-11-2, Benzoylstaurosporine 121181-53-1, Filgrastim 121263-19-2, Calphostin C 121288-39-9, Loxoribine 121547-04-4, Mirimostim 122111-03-9, Gemcitabine Hydrochloride 122341-38-2, Temoporfin 122431-96-3 122898-63-9, Phenazinomycin 123040-69-7, Azasetron 123258-84-4, Itasetron 123760-07-6, Zinostatin stimalamer 123774-72-1, Sargramostim 123830-79-5, Teloxantrone Hydrochloride 123948-87-8, Topotecan 124012-42-6, Galocitabine 124689-65-2D, Cryptophycin A, derivs. 124784-31-2, Erbulozole 124904-93-4, Ganirelix 125317-39-7, Vinorelbine Tartrate 125392-76-9, Acylfulvene 125533-88-2, Mofarotene 126297-39-0, Lissoclinamide 7 126443-96-7, Napavin 127984-74-1, Lanreotide Acetate 128505-88-4, Naphterpin 128768-09-2, Placetin A 128768-11-6, Placetin B 129497-78-5, Verteporfin 129564-92-7, Azatoxin 129655-21-6, Bizelesin 129731-10-8, Vorozole 130167-69-0, Pegaspargase 130288-24-3, Duocarmycin SA 130364-39-5, Rubiginone B1 130370-60-4, Batimastat 131190-63-1, Saintopin 132036-88-5, Ramosetron 132073-72-4, Tetrazomine 133432-71-0, Peldesine 134088-74-7, Nartograstim 134381-30-9, Conagenin 134523-84-5 134633-29-7, Tecogalan Sodium 134861-62-4, Dioxamycin 135257-45-3, Crambescidin 816 135381-77-0, Flezelastine 135383-02-7, Stipiamide 135558-11-1, Lobaplatin 135819-69-1 135968-09-1, Lenograstim 137018-54-3, Okicenone 137099-09-3, Turosteride 137219-37-5, Dehydrodidemnin B 137647-92-8, Axinastatin 1 137964-32-0 139755-79-6, Safingol Hydrochloride 140207-93-8, Pentosan polysulfate sodium 140703-49-7, Meterelin 142880-36-2, Ilomastat 144885-51-8, Sodium borocaptate 144916-42-7, Sonermin 145124-30-7, Bisnafide dimesylate 145858-50-0, Liarozole Hydrochloride 146426-40-6, Flavopiridol 148317-76-4, Oracin 148584-53-6 148717-58-2, Palauamine 148717-90-2, Squalamine 149204-42-2, Kahalalide F 149260-80-0, Mycaperoxide B 149355-77-1, Lamellarin-N triacetate

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

10690458

=> d 2 bib abs kwic

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1992:99301 CAPLUS
DN 116:99301
TI Maleic anhydride copolymers as antidotes for the cytotoxicity of neoplasm inhibitors
IN Bach, Ardalan; Shanahan, William R., Jr.
PA G.D. Searle and Co., USA
SO Eur. Pat. Appl., 27 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 393575	A1	19901024	EP 1990-107246	19900417
	EP 393575	B1	19940316		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	CA 2014732	AA	19901017	CA 1990-2014732	19900417
	JP 02292227	A2	19901203	JP 1990-101530	19900417
	AT 102838	E	19940415	AT 1990-107246	19900417
	ES 2062155	T3	19941216	ES 1990-107246	19900417
PRAI	US 1989-339503		19890417		
	EP 1990-107246		19900417		

OS MARPAT 116:99301
GI



I

AB Half-amide:half-imide copolymers comprising ethylene and maleic anhydride moieties (structure given), specifically carbetimer (I; a/b = 1:2-5), decrease the cytotoxic side effects of neoplasm inhibitors. Mice treated i.v. with 21 mg adriamycin/kg died within 5 days. When 1700 mg I/kg was administered concomitantly, no lethality was shown for >30 days.

IT 50-18-0, Cyclophosphamide 50-76-0, Dactinomycin 50-91-9, Floxuridine 51-21-8, 5-Fluorouracil 51-21-8D, conjugates with fibrinogens 53-19-0, Mitotane 54-42-2, NSC 39661 56-18-8, Norspermidine 57-22-7, Vincristine 59-05-2, Methotrexate 75-19-4D, Cyclopropane, spiro derivs. 113-15-5, ERgotamine 127-07-1 143-67-9, Vinblastine sulfate 147-94-4, Cytarabine 147-94-4D, Cytarabine, conjugates 154-42-7, Thioguanine 154-93-8, Carmustine 302-79-4, Retinoic acid 305-03-3, Chlorambucil 432-70-2, α-Carotene 636-65-7, Isoglutamine 642-18-2, Alstonine 645-05-6, Altretamine 671-16-9, Procarbazine 1149-99-1, Illudin 1404-00-8, Mitomycin 1404-64-4, Sparsomycin 1948-56-7D, Dehydroalanine, N-acyl derivative 2353-33-5, NSC 127716 3073-59-4, NSC 95580 3094-09-5, Doxifluridine 3778-73-2, Ifosfamide 4005-51-0, Aminothiadiazole 4342-03-4 4759-48-2, Isotretinoin 5373-42-2, Thaliblastine 6620-60-6, Proglumide 6829-55-6 7440-06-4D, Platinum, derivs., complexes 7481-89-2, Dideoxycytidine 7534-61-4, NSC 145813 9014-02-2D, Neocarzinostatin, conjugates with styrene-maleci acid copolymer 9015-68-3, Asparaginase 9041-93-4, Bleomycin sulfate 9054-89-1, Superoxide dismutase 10318-26-0, Mitolactol 12633-27-1, T 680 13010-47-4, Lomustine 13494-90-1, Gallium nitrate 13665-88-8, Mopidamol 13909-02-9 13909-09-6, Semustine 14459-29-1D, polymers 14930-96-2, Cytochalasin B 15219-97-3, Oxalysine 15663-27-1, Cisplatin 18378-89-7, Plicamycin 19624-67-0, SKF 101772 20830-81-3 21416-67-1, Razoxane 22862-76-6, Anisomycin 23214-92-8, Doxorubicin 23214-92-8D, conjugates with fibrinogens 24584-09-6, ICRF 187 25300-64-5D, conjugates with neocarzinostatin 26833-87-4, Homoharringtonine 27686-84-6, CHX 100 28656-91-9D, Aeroplysinin, derivs. 29069-24-7, Prednimustine 29767-20-2, Teniposide 31430-18-9D, Nocodazole, N-acyl derivative 33069-62-4, Taxol 33419-42-0, Etoposide 35144-64-0D,

10690458

Aldophosphamide, analogs 38077-12-2 39389-47-4, Distamycin
39544-74-6, Benzotript 40919-33-3, Uricytin 41575-94-4, Carboplatin
41729-52-6, Dezaguanine 41992-23-8, Spirogermanium 50264-69-2,
Lonidamine 51213-99-1, Clanfenur 51264-14-3, Amsacrine 51321-79-0,
PALA 51350-19-7, EHNA 52128-35-5, Trimetrexate 52205-73-9,
Estramustine phosphate sodium 53123-88-9, Rapamycin 53643-48-4,
Vindesine 53910-25-1, Pentostatin 54083-22-6, Zorubicin 54350-48-0,
Etretinate 54526-94-2, Steffimycin B **54824-17-8**, Mitonafide
55073-32-0, Genkwadaphnin 55079-83-9, Acitretin 55303-98-5, Avarol
56281-36-8, Motretinide 56420-45-2, Epirubicin 56605-16-4,
Spiromustine 56973-26-3, SM 108 57248-88-1 57576-44-0, Aclarubicin
58066-85-6, Hexadecylphosphocholine 58196-43-3 58337-35-2, Elliptinium
acetate 58338-59-3, Dinaline 58957-92-9 58994-96-0, Ranimustine
59040-30-1, Nafazatrom 59653-73-5, Teroxirone 60084-10-8, Tiazofurin
60784-46-5, Elmustine 61251-97-6, Baccharin 61422-45-5, Carmofur
61825-94-3, Oxaliplatin 62396-95-6 62488-57-7, NSC 26480 62816-98-2,
Tetraplatin 62928-11-4, Iproplatin 63521-85-7, Esorubicin
64124-21-6, Trimelamol 65222-35-7, Pazelliptine 65271-80-9,
Mitoxantrone 65646-68-6, Fenretinide 65794-79-8, Gregatin A
65886-71-7, Fazarabine 66052-62-8, NSC 264394 67199-66-0, Batracylin
67699-40-5, Vinzolidine 67995-68-0, Tallysomycin 68247-85-8
69408-81-7, Amonafide 69772-39-0, Neoenactin 69839-83-4, Didox
69955-43-7, α-Difluoromethylarginine 70189-62-7, TA 077
71103-05-4, Stypoldione 71240-74-9, GYKI 17230 71486-22-1, Vinorelbine
71628-96-1, Menogaril 72238-02-9, Retelliptine 72496-41-4, Pirarubicin
72732-56-0, Piritrexim 72880-48-9, K-AM 73387-70-9, DABIS
maleate 73612-99-4, CA 102 74427-64-8, NSC 342215
75219-46-4, Bestrabucil 75607-67-9, Fludarabine phosphate 76520-52-0,
Spatol 77327-05-0, Didemnin B 77699-47-9, Herbimycin 77739-71-0,
Acanthifolic acid 78186-34-2, Bisantrene 78287-27-1, SN 22
80205-24-9, Cyplatate 80427-58-3, Benfluron 80576-83-6, CGP 30694
80667-13-6, FO-152 80681-73-8, KI-8110 80790-68-7, ADR 456
80841-47-0, CI-921 81424-67-1, Caracemide 81485-25-8 81600-06-8,
Vintriptol 83150-76-9, Octreotide 83314-01-6, Bryostatin 1
83373-60-8, D 609 83519-04-4, Ilmofosine 83947-09-5, Antibiotic AN 3
83996-50-3 83997-75-5, FCE 21954 84396-34-9, SS 554 85233-29-0,
BMY-28438 85326-06-3 85622-93-1, Temozolomide 85700-43-2
85969-07-9, Budotitane 85977-49-7, Tauromustine 86229-97-2, RA 700
87385-19-1 87790-39-4, SUN 0237 87810-56-8, Fostriecin 87859-14-1
88266-67-5, NK-313 88303-61-1, CI-941 88859-04-5, Mafosfamide
88895-06-1, Esperamicin A1b 89196-07-6, NSC 357704 90072-82-5
90996-54-6, Rhizoxin 91265-19-9 91441-23-5, Piroxantrone 91441-48-4,
CI-937 91531-30-5, Antineoplaston A10 91531-98-5, Amphethinile
91753-07-0, Mitoquidone 92090-94-3, Kazusamycin 92118-27-9,
Fotemustine 92211-45-5, SUN 2071 92455-12-4, AD 5 92803-82-2
95056-36-3, BMY-25067 95058-81-4, LY 188011 95458-43-8, MZPES
95604-83-4, Probimane 95693-76-8, DATHF 95734-82-0, 254S 96086-68-9,
DN-9693 96201-88-6, Brequinar sodium 96203-70-2, Pancratistatin
96389-68-3, Crisnatol 96497-67-5, Rodorubicin 96892-57-8, Hepsulfam
97068-30-9, Elsamicin-A 97534-21-9, Merbarone 97919-22-7 98227-64-6,
SS 9816B 98383-18-7, CY 233 98629-43-7, NKT 01 98631-95-9, MST-16
98985-36-5, DM-75 99009-20-8, PD-115934 99107-03-6, BL 6859
99107-06-9, BMY-26605 99212-42-7, Anaxirone 99674-26-7, Esperamicin-A1
99755-38-1 100286-90-6, CPT11 100415-25-6, Sorangicin A 100438-92-4,
Normosang 100440-25-3, Terpentecin 100753-80-8, SN 07 100827-28-9,
Erbstatin 101156-09-6, Chromoximycin 102363-08-6, FR-900482
102636-25-9, TAC-788
RL: PRP (Properties)
(cytotoxicity of, maleic anhydride copolymer antidote for)

=> d his

10690458

=> d bib abs kwic

L8 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:855913 CAPLUS
DN 139:350646
TI Preparation of amonafide salts as anticancer agents
IN Ajami, Alfred M.; Barlow, David
PA Xanthus Life Sciences, Inc., Can.
SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003089415	A1	20031030	WO 2003-US12619	20030422
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003203932	A1	20031030	US 2002-128129	20020422
	US 6693198	B2	20040217		
	JP 2003321452	A2	20031111	JP 2002-197809	20020705
PRAI	US 2002-128129	A2	20020422		

OS MARPAT 139:350646
GI



I

AB Salts of amonafide or amonafide analogs I [R1 = (un)substituted NH2, aminoalkyl; R2 = OH, alkoxy, (un)substituted NH2, SO3H, NO2, acyloxy; X = carboxylate] were prepared Thus, 3-nitro-1,8-naphthalic anhydride was treated with Me2NCH2CH2NH2, followed by L-malic acid to give mitonafide **malate** which was reduced over Pd/C to give amonafide **malate**. This compound was completely soluble in H2O and normal saline solution and had anticancer activity both in vitro and in vivo.
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT
AB Salts of amonafide or amonafide analogs I [R1 = (un)substituted NH2, aminoalkyl; R2 = OH, alkoxy, (un)substituted NH2, SO3H, NO2, acyloxy; X = carboxylate] were prepared Thus, 3-nitro-1,8-naphthalic anhydride was treated with Me2NCH2CH2NH2, followed by L-malic acid to give mitonafide **malate** which was reduced over Pd/C to give amonafide **malate**. This compound was completely soluble in H2O and normal saline solution and had anticancer activity both in vitro and in vivo.
IT 108-00-9, N,N-Dimethylethylenediamine 3027-38-1, 3-Nitro-1,8-naphthalic anhydride **69408-81-7**, Amonafide
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of amonafide salts as anticancer agents)